Issue Date: September 19, 2016
Catalent will buy Pharmatek Labs
Catalent is buying San Diego-based Pharmatek Laboratories for an undisclosed amount. The purchase will add early-stage dosage-form drug development capabilities, analytical services, and clinical-scale manufacturing to Catalent’s drug delivery and formulation business. In particular, Catalent will gain spray-drying technology and expand its ability to handle highly potent compounds. Pharmatek works on oral, injectable, and topical products for more than 100 customers, the companies say.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society